hepatitis%20c
HEPATITIS C

Hepatitis C can be transmitted through blood transfusions, organ transplants, percutaneous (especially IV drug use), sexual or perinatal route.

It has an incubation period of 14-180 days.

Goal of treatment is to prevent progression to chronic hepatitis C through antiviral treatment of acute hepatitis C. Also, it aims to prevent occurrence of liver-related complications through antiviral treatment of chronic hepatitis C.

Patient Education

Partner Notification

  • Partner notification for at-risk contacts
    • Contact tracing to include any sexual contact (penetrative vaginal or anal sex) or needle-sharing partners from 2 weeks before the onset of jaundice
    • If without acute infection, trace back to the likely time of infection eg blood transfusion, 1st needle sharing

Patient Education

  • Provide the patients with a detailed explanation of their condition
    • Emphasize the disease’s long-term implications for their and their partners’ health
    • Provide clear, accurate, written information
  • Advise patient not to donate blood, semen or organs
  • Advise patient to avoid sharing items of personal hygiene eg toothbrushes, shaving equipment
  • Counsel patient to stop using illicit drugs
  • Advise patient regarding sexual transmission
    • HCV is not considered to be a sexually transmitted disease, but sexual promiscuity, HIV and herpes simplex virus (HSV-2) co-infections are associated with sexual transmission of hepatitis C
    • Avoid unprotected sex during menstruation
  • Advise patient regarding the potential deleterious effect of alcohol especially in association with development of HCC, progression of liver fibrosis and increase in HCV replication
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 14 Aug 2018
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Roshini Claire Anthony, 12 Jul 2019

Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.